BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 25083076)

  • 21. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?
    Sakhuja P
    World J Gastroenterol; 2014 Nov; 20(44):16474-9. PubMed ID: 25469015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease.
    Brunt EM; Wong VW; Nobili V; Day CP; Sookoian S; Maher JJ; Bugianesi E; Sirlin CB; Neuschwander-Tetri BA; Rinella ME
    Nat Rev Dis Primers; 2015 Dec; 1():15080. PubMed ID: 27188459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiologic evaluation of nonalcoholic fatty liver disease.
    Lee SS; Park SH
    World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acidophil bodies in nonalcoholic steatohepatitis.
    Yeh MM; Belt P; Brunt EM; Kowdley KV; Wilson LA; Ferrell L;
    Hum Pathol; 2016 Jun; 52():28-37. PubMed ID: 26980020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
    Wiering L; Subramanian P; Hammerich L
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathology, grading and staging of nonalcoholic fatty liver disease.
    Kleiner DE
    Minerva Gastroenterol Dietol; 2018 Mar; 64(1):28-38. PubMed ID: 28948754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
    Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of nonalcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Duodecim; 2016; 132(22):2099-106. PubMed ID: 29190058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semi-Quantitative Ultrasonographic Evaluation of NAFLD.
    Ballestri S; Tana C; Di Girolamo M; Fontana MC; Capitelli M; Lonardo A; Cioni G
    Curr Pharm Des; 2020; 26(32):3915-3927. PubMed ID: 32303161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.